Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
WEB1 day ago — October 1, 2024 at 12:26 PM EDT. Save. Sanofihas asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a ...
Sanofi US News
WEB5 days ago — Dupixent approved in the US as the first-ever biologic medicine for patients with COPD. Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype. Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 …
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
WEB2 days ago — Dupixent is a key top-line driver for both Sanofi and Regeneron on strong demand trends. In the first half of 2024, Dupixent generated global product sales of $€6.1 billion, which were recorded ...
Dupixent Gets FDA Approval for COPD - WebMD
WEB18 hours ago — Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...
Latest Sanofi Press Releases and News | Sanofi
WEBSep 20, 2024 — Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEBSanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U ...
Sanofi gets two bids valuing its consumer health unit at about
WEB(Reuters) -Sanofi has received two separate bids from private equity firms for its consumer health unit, which could be valued at 15 billion euros ($16.74 billion) or more, Bloomberg News reported ...
US FDA approves Sanofi-Regeneron's Dupixent for 'smoker's …
WEBThe approval is expected to add billions of dollars in sales for the treatment, which is one of the top-selling drugs for both the companies. Sanofi recorded 10.72 billion euros ($11.94 billion ...
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 — The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 — Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.